📋 Tender Overview
Contract awarded for Amgros 2027 1.486.a lot-0003, title: tender number 3, description: the tender number (subcontract) includes the following medicines: atc code: b01ab04 · generic name: dalteparin · dispensing form: injection solution, syringe · strength: 2500 anti-xa iu · unit value: 2.5 tu · quantity in units: 106025 ··· atc code: b01ab04 · generic name: dalteparin · dispensing form: injection solution, syringe · strength: 5000 anti-xa iu · unit value: 2.5 tu · quantity in units: 985430 ··· atc code: b01ab04 · generic name: dalteparin · dispensing form: injection solution, syringe · strength: 7500 anti-xa iu · unit value: 2.5 tu · quantity in units: 24033 ··· atc code: b01ab04 · generic name: dalteparin · dispensing form: injection solution, syringe · strength: 10000 anti-xa iu · unit value: 2.5 tu · quantity in units: 254100 ··· atc code: b01ab04 · generic name: dalteparin · dispensing form: injection solution, syringe · strength: 12500 anti-xa iu · unit value: 2.5 tu · quantity in units: 70220 ··· atc code: b01ab04 · generic name: dalteparin · dispensing form: injection solution, syringe · strength: 15000 anti-xa iu · unit value: 2.5 tu · quantity in units: 423540 ··· atc code: b01ab04 · generic name: dalteparin · dispensing form: injection solution, syringe · strength: 18000 anti-xa iu · unit value: 2.5 tu · quantity in units: 78221. each tender number is considered an independent subcontract and is tendered independently of the other tender numbers. a supplier may therefore choose to submit bids for one, several, or all tender numbers, and awards are made separately for each individual tender number. a supplier may therefore be awarded one, several, or all subcontracts. reference is made to the tender conditions, including the submission of bids under the individual tender numbers. under the designation 'quantity in units' above, an estimated consumption of the medicines under the tender number is indicated, but the actual consumption may deviate significantly from this. suppliers must take this into account. the reason for this is that these are medicines for patient treatment in public hospitals, where the patient's needs must be met. the tendered medicines are also covered by one or more recommendations and/or treatment guidelines from the medicines council, and the consumption of the various medicines may be significantly influenced by this. for a more detailed description, reference is made to the tender conditions and the framework agreement. the maximum value of the subcontract below under item 5.1.5 is calculated as a share of 70% of the estimated total value of all subcontracts listed in item 2.1.3. this is based on the fact that all the tendered medicines are covered by one or more recommendations and/or treatment guidelines from the medicines council, which assesses which of the tendered medicines are recommended for treatment for different patient populations, possibly so that certain medicines are considered equally possible first choices, recommended for use in prioritized order or similar. the medicines council's assessment can therefore have significant importance for which of the tendered medicines are used within different therapeutic areas and patient populations, and the consumption of the individual medicines may also depend on applicable contract prices. this means that it is not possible to estimate which medicines will primarily be used during the term of the framework agreement, and it is possible that the use of the medicines may change significantly during the term of the framework agreements, particularly with the approval of new indications for the individual medicines, changed treatment of one or more patient populations, and similar. the determination of the maximum value of the individual subcontracts as a share of the total estimated quantity of all subcontracts aims to ensure that each of the entered framework agreements can be used for the necessary procurement. the maximum value is thus set based on a professional assessment of the potential use of the medicines considering the special circumstances regarding the use of medicines in public hospitals and the significant importance that the medicines council's recommendation and/or treatment guidelines may have for the actual consumption of the individual medicines, including significant changes in the consumption of the various medicines. estimated value excluding vat: 176325081.00 dkk.Amgros 2027 1.486.a
